Browsing Tag
Pelareorep
5 posts
A durability breakthrough or early signal? What pelareorep means for resistant colorectal cancer
Can durability redefine MSS colorectal cancer? Discover how Oncolytics Biotech, Inc.’s pelareorep data could shift treatment strategy and market dynamics.
How the FDA meeting could redefine pelareorep’s registrational path in anal cancer
Could Oncolytics Biotech redefine pelareorep’s approval path in anal cancer? Read what the FDA meeting means for commercialization and investor sentiment.
Is pelareorep gaining traction? Oncolytics Biotech’s updated GOBLET data draws investor focus to third-line anal cancer
Find out why Oncolytics Biotech’s updated GOBLET cohort 4 data is drawing investor attention to pelareorep’s role in third-line anal cancer.
Breakthrough trial: Oncolytics Biotech’s pelareorep combo doubles response rate in advanced anal cancer
Find out how Oncolytics Biotech’s breakthrough trial doubled response rates in advanced anal cancer and set up a 2026 FDA path.
Oncolytics Biotech signs $20m share purchase deal with Alumni Capital to advance pelareorep development
Oncolytics Biotech inks $20M share deal with Alumni Capital to support pelareorep trials in breast and pancreatic cancer. Read how the biotech firm is advancing.